/

Società

Va

Non verificato

Vaxxas

Di cosa scriviamo

Attrezzature medico-sanitarieBiotecnologiaIndustriaMedicina - VarieSalute

9 comunicati stampa

Guarda tutti i comunicati

18/03/2025

Industria

Salute

Attrezzature medico-sanitarie

HIV, AIDS e malattie autoimmuni

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

Vaxxas Secures New U.S. Patent For its Needle-Free Vaccination Manufacturing Technology

Fonte

Emittente

1.00

0

04/03/2025

Industria

Oncologia

Salute

Attrezzature medico-sanitarie

HIV, AIDS e malattie autoimmuni

Medicina - Varie

Farmaceutica

Biotecnologia

Newly Published Data Supports Effective Delivery of DNA-Based Vaccines Using Vaxxas’ High-Density Microarray Patch (HD-MAP) Delivery Technology

Fonte

Emittente

1.00

0

18/02/2025

Industria

Salute

Igiene alimentare

Attrezzature medico-sanitarie

HIV, AIDS e malattie autoimmuni

Medicina - Varie

Farmaceutica

Biotecnologia

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

Fonte

Emittente

1.00

0

05/02/2025

Salute

Attrezzature medico-sanitarie

HIV, AIDS e malattie autoimmuni

Medicina - Varie

Farmaceutica

Biotecnologia

Mercato del lavoro

Vaxxas Appoints Leading Global Vaccine Experts as the Company Advances its Needle-Free Vaccination Technology Towards Late-Stage Clinical Trials

Fonte

Emittente

1.00

0

22/01/2025

Mercato del lavoro

Industria

Scienza

Biotecnologia

Farmaceutica

Salute

Attrezzature medico-sanitarie

HIV, AIDS e malattie autoimmuni

Medicina - Varie

Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines

Fonte

Emittente

1.00

0

13/01/2025

Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination

Fonte

Emittente

1.00

0

24/11/2024

Industria

Scienza

Assistenza all'Infanzia

Attrezzature medico-sanitarie

Medicina - Varie

Biotecnologia

Salute

Sanità

Vaxxas Expands Global Intellectual Property Portfolio for Exclusive Manufacture and Sale of Needle-Free Vaccination Technology

Fonte

Emittente

1.00

0

28/10/2024

Mercato del lavoro

Industria

Biotecnologia

Farmaceutica

Attrezzature medico-sanitarie

Sanità

Salute

HIV, AIDS e malattie autoimmuni

Medicina - Varie

Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)

Fonte

Emittente

1.00

0

11/09/2024

Vaxxas Initiates Phase I Clinical Trial of Pre-Pandemic Avian Influenza A Virus (H7N9) Vaccine Delivered Using Vaxxas’ Novel High-Density Microarray Patch (HD-MAP)

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0